Shiihara Takashi, Miyake Taeko, Izumi Sakiko, Sugihara Susumu, Watanabe Mio, Takanashi Jun-ichi, Kubota Masaya, Kato Mitsuhiro
Department of Neurology, Gunma Children's Medical Center, 779 Shimohakoda, Hokkitsu-machi, Shibukawa, Gunma 377-8577, Japan.
Department of Laboratory Medicine, Gunma Children's Medical Center, 779 Shimohakoda, Hokkitsu-machi, Shibukawa, Gunma 377-8577, Japan.
Brain Dev. 2014 Jun;36(6):489-95. doi: 10.1016/j.braindev.2013.06.011. Epub 2013 Jul 11.
There have been numerous reports regarding serum or cerebrospinal fluid (CSF) biomarkers in various disorders; however, the validities of such biomarkers for more precise diagnoses and prognosis estimates remain to be determined, especially in pediatric patients with neurological disorders.
Serum/CSF S100B, neuron-specific enolase, and total tau (tTau) were measured in various acute pediatric neurological disorders, and their usefulness for diagnostic and prognostic predictions was validated using receiver operating characteristic curves and area under the curve (AUC) analysis.
A total of 336 serum and 200 CSF specimens from 313 patients were examined, and we identified statistically significant differences that were relevant from diagnostic and prognostic viewpoints. CSF and serum tTau levels could be good predictors for diagnosis (CSF tTau; AUC=0.76) and prognosis (serum tTau; AUC=0.78).
Both CSF and serum tTau levels could be useful for precise diagnostic and prognostic estimations in acute pediatric neurological disorders. Further studies are needed to clarify the clinical significance of such biomarkers.
关于各种疾病中血清或脑脊液（CSF）生物标志物的报道众多；然而，此类生物标志物用于更精确诊断和预后评估的有效性仍有待确定，尤其是在患有神经系统疾病的儿科患者中。
对各种急性儿科神经系统疾病患者的血清/脑脊液S100B、神经元特异性烯醇化酶和总tau蛋白（tTau）进行检测，并使用受试者工作特征曲线和曲线下面积（AUC）分析验证其对诊断和预后预测的有用性。
共检测了313例患者的336份血清和200份脑脊液样本，我们发现了从诊断和预后角度来看具有统计学意义的差异。脑脊液和血清tTau水平可能是诊断（脑脊液tTau；AUC = 0.76）和预后（血清tTau；AUC = 0.78）的良好预测指标。
脑脊液和血清tTau水平均可用于急性儿科神经系统疾病的精确诊断和预后评估。需要进一步研究以阐明此类生物标志物的临床意义。
